Quantification of mycophenolic acid and glucuronide metabolite in human serum by HPLC-tandem mass spectrometry

被引:45
作者
Annesley, TM [1 ]
Clayton, LT [1 ]
机构
[1] Univ Michigan, Ctr Hlth Sci, Dept Pathol, Ann Arbor, MI 48109 USA
关键词
D O I
10.1373/clinchem.2004.047357
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The potent immunosuppressant mycophenolic acid (MPA) is metabolized to an, inactive glucuronide (MPAG). The extent of metabolism. varies among individuals, and the MPAG formed can be hydrolyzed to MPA and can displace MPA from serum albumin, treating a potential need to monitor both MPA and MPAG. Methods After addition of the carboxybutoky ether of MPA (MPAC) as internal standard, MPA and MPAG. were isolated from serum by acidification followed by solid-phase extraction. Gradient chromatographic separation was performed on a Waters Atlantis reversed-phase liquid chromatography (HPLC) column, and the compounds were quantified by electrospray ionization tandem mass spectrometry (MS/MS) in the multiple-reaction monitoring mode. Results obtained by HPLC-MS/MS were compared with an HPLC assay using ultraviolet detection (HPLC-UV) performed at a reference laboratory. Results: MPAG, MPA, and MPAC were fully separated during a 7.0-min run time. Precision at both low and high concentrations of MPA ad MPAG met the suggested method validation criteria from a consensus panel report on MPA.,The extraction efficiencies were 99% for MPA and MPAG. The assay was linear to 16 mg/L for MPA and 200 mg/L for MPAG. Limits of quantification Were 0.1 mg/L for MPA and 1 mg/L for MPAG. Regression analysis gave the following results: HPLC-MS/MS = 1.03(HPLC-UV) 0.03 mg/L (R 2 0.982) for MPA; and HPLC-MS/MS 0.93(HPLC-UV) + 0.89 mg/L (R-2 = 0.967) for MPAG. Conclusion: This HPLC-MS/MS assay can be used to reproducibly quantify MPA and MPAG across a large analytical range in serum from organ transplant patients. (c) 2005 American Association for Clinical Chemistry.
引用
收藏
页码:872 / 877
页数:6
相关论文
共 15 条
[1]   Simple extraction protocol for analysis of immunosuppressant drugs in whole blood [J].
Annesley, TM ;
Clayton, L .
CLINICAL CHEMISTRY, 2004, 50 (10) :1845-1848
[2]   Ion suppression in mass spectrometry [J].
Annesley, TM .
CLINICAL CHEMISTRY, 2003, 49 (07) :1041-1044
[3]  
[Anonymous], 2001, Bioanalytical method validation: guidance for industry
[4]   Quantification of free mycophenolic acid and its glucuronide metabolite in human plasma by liquid-chromatography using mass spectrometric and ultraviolet absorbance detection [J].
Atcheson, B ;
Taylor, PJ ;
Mudge, DW ;
Johnson, DW ;
Pillans, PI ;
Tett, SE .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 799 (01) :157-163
[5]   Clinical pharmacokinetics of mycophenolate mofetil [J].
Bullingham, RES ;
Nicholls, AJ ;
Kanmm, BR .
CLINICAL PHARMACOKINETICS, 1998, 34 (06) :429-455
[6]   Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure [J].
Kaplan, B ;
Gruber, SA ;
Nallamathou, R ;
Katz, SM ;
Shaw, LM .
TRANSPLANTATION, 1998, 65 (08) :1127-1129
[7]  
National Committee for Clinical Laboratory Standards, 1992, EP5T2 NCCLS
[8]   Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry [J].
Patel, CG ;
Mendonza, AE ;
Akhlaghi, F ;
Majid, O ;
Trull, AK ;
Lee, T ;
Holt, DW .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 813 (1-2) :287-294
[9]  
Prémaud A, 2004, THER DRUG MONIT, V26, P609
[10]   Bioanalytical Method Validation—A Revisit with a Decade of Progress [J].
Vinod P. Shah ;
Kamal K. Midha ;
John W. A. Findlay ;
Howard M. Hill ;
James D. Hulse ;
Iain J. McGilveray ;
Gordon McKay ;
Krys J. Miller ;
Rabindra N. Patnaik ;
Mark L. Powell ;
Alfred Tonelli ;
C. T. Viswanathan ;
Avraham Yacobi .
Pharmaceutical Research, 2000, 17 (12) :1551-1557